About me

Dr. Peter Sayre specializes in adult bone marrow transplantation and other treatments for leukemia, multiple myeloma, lymphoma and Hodgkin's disease.

Sayre is a director of clinical research at UCSF. His research interests focus on allogeneic stem cell transplants (which use cells from a matching donor) and leukemia in older adults. His work on these subjects has been widely published in medical and other scientific journals.

Sayre earned an undergraduate degree in philosophy from Yale College, graduating magna cum laude. He earned his medical degree at the Rutgers Robert Wood Johnson Medical School, and he earned a doctorate in immunology at Harvard University. He completed a fellowship in hematology and oncology at UCSF before joining the faculty in 1996.

  • Education

    Robert Wood Johnson Medical School, 1990

  • Residencies

    UC San Diego, Internal Medicine, 1993

  • Fellowships

    UCSF, Oncology, 1996

    UCSF, Hematology, 1996

  • Academic Title

    Professor

  • Languages

    French

    Spanish

Cancer Immunotherapy Clinic

Bakar Precision Cancer Medicine Building

1825 Fourth St., Fifth Floor
San Francisco, CA 94158

Hematology and Blood and Marrow Transplant

400 Parnassus Ave., Fourth Floor
San Francisco, CA 94143

My reviews

4.8

Overall Experience
40 Reviews
Dr Sayre was excellent. Very thorough and communicates well!
Explained things in a way that was easy to understand
39 Reviews
Did the doctor pay attention to your concerns
40 Reviews
Gave easy to understand instructions about taking care of health problems or concerns
39 Reviews
Knew the important information about your medical history
40 Reviews
The provider showed respect for what you had to say
40 Reviews
The provider spent enough time with me
39 Reviews
Decorative Caduceus

Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/Hi...

• Maximum Tolerated Dose/Schedule: the MTDS will be defined as the highest dose/schedule administered during any Cohort in the study at which the incidence of DLT is < 33% during the first cycle of MGD006 treatment.

Recruiting

Share